Bio Techne Valuation
| TECH Stock | USD 60.26 0.57 0.94% |
At this time, the firm appears to be fairly valued. Bio Techne Corp shows a prevailing Real Value of $61.52 per share. The current price of the firm is $60.26. Our model approximates the value of Bio Techne Corp from analyzing the firm fundamentals such as Return On Equity of 0.038, current valuation of 9.64 B, and Profit Margin of 0.06 % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Bio Techne's price fluctuation is very steady at this time. Calculation of the real value of Bio Techne Corp is based on 3 months time horizon. Increasing Bio Techne's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bio Techne is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Techne's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 60.26 | Real 61.52 | Hype 69.45 | Naive 55.61 |
The intrinsic value of Bio Techne's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bio Techne's stock price.
Estimating the potential upside or downside of Bio Techne Corp helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Techne more accurately as focusing exclusively on Bio Techne's fundamentals will not take into account other important factors: Bio Techne Total Value Analysis
Bio Techne Corp is at this time forecasted to have valuation of 9.64 B with market capitalization of 9.39 B, debt of 444.06 M, and cash on hands of 247.03 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bio Techne fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.64 B | 9.39 B | 444.06 M | 247.03 M |
Bio Techne Investor Information
About 100.0% of the company shares are owned by institutional investors. The book value of Bio Techne was at this time reported as 12.62. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Bio Techne Corp last dividend was issued on the 17th of November 2025. The entity had 4:1 split on the 30th of November 2022. Based on the measurements of operating efficiency obtained from Bio Techne's historical financial statements, Bio Techne Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Bio Techne Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bio Techne has an asset utilization ratio of 47.68 percent. This signifies that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Bio Techne Corp is more efficient with each dollar of assets it utilizes for everyday operations.Bio Techne Ownership Allocation
The majority of Bio Techne Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Techne Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne Corp as this could imply that something significant has changed or is about to change at the company. On November 5, 2025, Representative April Delaney of US Congress acquired under $15k worth of Bio Techne Corp's common stock.Bio Techne Profitability Analysis
The company reported the previous year's revenue of 1.22 B. Net Income was 73.4 M with profit before overhead, payroll, taxes, and interest of 813.2 M.Bio Techne Past Distributions to stockholders
About Bio Techne Valuation
An absolute valuation paradigm, as applied to Bio Stock, attempts to find the value of Bio Techne Corp based on its fundamental and basic technical indicators. By analyzing Bio Techne's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bio Techne's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bio Techne. We calculate exposure to Bio Techne's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bio Techne's related companies.Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people.
A single share of Bio Techne represents a small ownership stake in the entity. As a stockholder of Bio, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Bio Techne Dividends Analysis For Valuation
There are various types of dividends Bio Techne can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Bio shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Bio Techne Corp directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Bio pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Bio Techne by the value of the dividends paid out.
Bio Techne Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 159.7 M | |
| Quarterly Earnings Growth Y O Y | 0.143 | |
| Forward Price Earnings | 30.3951 |
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |